Desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor (SNRI), reduces hot flashes by about 64% after 3 months of use, according to the results of a double-blind, placebo-controlled trial.
Desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor (SNRI), reduces hot flashes by about 64% after 3 months of use, according to the results of a double-blind, placebo-controlled trial.
Researchers randomized 707 healthy postmenopausal women experiencing 50 or more moderate-to-severe hot flushes per week to either desvenlafaxine 50, 100, 150, or 200 mg or placebo daily for 52 weeks.
Desvenlafaxine 100 mg/d significantly reduced the average daily number of hot flushes compared with placebo at weeks 4 (P=.013) and 12 (P=.005). In addition, compared with placebo, 12 weeks of 100 mg/d of the drug significantly reduced the severity of hot flushes and was associated with a significantly higher 75% responder rate (50% for desvenlafaxine vs. 29% for placebo). Efficacy, as measured by a 50% reduction from baseline in number of hot flushes, was reached within 1 week of treatment, compared with 3 to 4 weeks for placebo. And desvenlafaxine significantly reduced nighttime awakenings due to hot flushes.
Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111: 77–87.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More